KMPHARMACEUTICAL Co., Ltd.
KKRX:225430698.00
KRW
+16.00
(+2.35%)
ISIN
KR7225430008
Return %
Stock
S&P 500
1Y
-78.52
14.39
3Y
-87.99
81.42
5Y
-94.34
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 63
- Sector
- Consumer non-durables
- Industry
- Household/Personal care
- Address
- Pyeongtaek-si South Korea
- IPO Date
- Oct 8, 2015
- Website
- kmkmp.com
- Similar Companies
- Business
- KMPHARMACEUTICAL Co., Ltd. is a South Korea-based company primarily engaged in the research, development, manufacture, and distribution of oral care products, functional cosmetics, personal care goods, and household quasi-drugs, as well as the provision of comprehensive original equipment manufacturing (OEM) and original design manufacturing (ODM) services. Founded in 2001 and headquartered in Pyeongtaek-si, Gyeonggi-do, South Korea, the company operates dual dedicated production facilities consisting of Plant 1 for quasi-drugs and oral hygiene products and Plant 2 for cosmetics and personal care formulations. The company's product and service portfolio encompasses three primary divisions: Oral Care, Beauty and Personal Care, and Household and Daily Necessities. In Oral Care, the company manufactures and markets pediatric and adult toothpastes, including character-licensed toothpastes under the Pororo brand; specialized oral hygiene solutions under the FOAMGLE brand; manual and specialized toothbrushes; antibacterial mouthwashes and gargles; patented dual-phase mouth rinse formulations; and foam-dispensing cleansers for dentures and orthodontic aligners. In Beauty and Personal Care, the company offers scalp care and anti-hair-loss shampoos and treatments under the nano-graphene-infused Zerocipe brand; infant and toddler skincare solutions under the ATOBIOME brand; facial sun care and moisturizing emulsions, including Nano Centella Sun Essence; hair coloring products; body washes; and character-themed personal care lines featuring Seoul Metropolitan Government's Hechi character. In Household and Daily Necessities, the company produces sanitary wet wipes; antibacterial hand sanitizers; protective face masks; and household dehumidifiers. Through its contract manufacturing operations, the company provides turnkey formulation, regulatory documentation, and production services for third-party domestic and international brand owners. Geographically, KMPHARMACEUTICAL distributes its products domestically across pharmacy networks, hypermarkets, health and beauty store chains such as Olive Young, and online commerce channels, while exporting to international markets including China, Vietnam, Malaysia, Thailand, North America, the Middle East, and Latin America under US FDA cGMP-compliant manufacturing standards. In recent corporate developments, KMPHARMACEUTICAL has accelerated the commercialization of proprietary functional brands, broadened its global commercial partnerships, and diversified into high-margin healthcare segments. The company deepened its strategic partnership with Swiss natural cosmetic and pharmaceutical firm Weleda for the co-development and contract supply of oral care products, achieving over KRW 7.0 billion in cumulative production revenue. In Southeast Asia, the company established cross-border distribution agreements with Malaysia's retail operator Cosway and Thailand's ADMI to distribute its Zerocipe personal care lines, alongside entering an annual commercial supply agreement with General Brands. On the product innovation front, KMPHARMACEUTICAL introduced the ATOBIOME infant care brand, patented a novel dual-phase mouth rinse composition, secured patent registrations for foaming orthodontic appliance cleaners, and launched specialized sun care products co-developed with digital creators. Operationally, the company is advancing regulatory clearances to enter the medical aesthetics market while implementing a production optimization plan targeting KRW 90.0 billion in total annual production capacity by 2028.